Welcome to our dedicated page for Xenon Pharmaceut news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceut stock.
Xenon Pharmaceuticals Inc. reports news on its neuroscience-focused biopharmaceutical pipeline, including drug discovery, clinical development and commercialization plans for neurological and psychiatric disorders. The company’s lead molecule, azetukalner, is a KV7 potassium channel opener in Phase 3 clinical development for epilepsy, major depressive disorder and bipolar depression.
Recurring updates include azetukalner clinical data in focal onset seizures, presentations at medical and investor conferences, financial results, business updates, public offerings, inducement equity grants and early-stage potassium and sodium channel programs, including KV7 and NaV1.7 candidates being developed for pain.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will present at the BofA Securities Health Care Conference 2024. The presentation will take place on May 15, 2024, in Las Vegas, NV, featuring the company's President, CEO, and CFO. The webcast will be available on the company's website for replay. Xenon is a neuroscience-focused biopharmaceutical company dedicated to developing therapeutics for neurological and psychiatric disorders, such as epilepsy and depression.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will present at the 2024 RBC Capital Markets Global Healthcare Conference. The event will take place on May 14-15, 2024, in New York, NY. Presenters include Ian Mortimer, President and CEO, and Sherry Aulin, CFO. The company focuses on neuroscience, aiming to develop therapeutics for neurological and psychiatric disorders. Xenon's live webcast will be available on their website for replay.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will report its first quarter 2024 financial results on May 9, 2024. The company focuses on neuroscience and aims to develop innovative therapeutics for neurological and psychiatric disorders. Xenon encourages participants to pre-register for the conference call/webcast to discuss the results. The company is committed to addressing high unmet medical needs in areas such as epilepsy and depression.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.